Rongdean Chen

Suggest Changes
Learn More
BACKGROUND In the phase III double-blind Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2, apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated(More)
BACKGROUND The Physician Global Assessment and Body Surface Area (PGAxBSA) composite tool is a simple, effective alternative for measuring psoriasis severity. OBJECTIVE To evaluate the product of(More)
BACKGROUND Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis. OBJECTIVE Assess long-term safety of oral(More)
BACKGROUND Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact on quality of life. OBJECTIVE We evaluated the efficacy and safety of apremilast in palmoplantar(More)
  • 1